AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Praxis Precision Medicines Inc (NASDAQ:PRAX)
43.855 USD
-0.705 1.582%| Previous Close (in USD) | 44.56 |
|---|---|
| Change | -0.705 1.582% |
| 52 W H/L (in USD) | 67.210/12.450 |
| EBITDA (in USD) | -129.73M |
| PE Ratio | -- |
| Volume | 58805 |
| Diluted Eps TTM | -11.27 |
| Total Assets (in USD) | 87.948M |
|---|---|
| Total Liabilities (in USD) | 18.279M |
| Revenue TTM (in USD) | 2.195M |
| Cash (in USD) | 81.3M |
| Market Cap (in USD) | 773.448 M |
| Revenue Per Share TTM | 0.239 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Employees: 82
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Marcio Souza M.B.A. | Pres, CEO & Director | 1980 |
| 2. | Ms. Nicole Sweeny | Chief Commercial Officer | 1975 |
| 3. | Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer | NA |
| 4. | Mr. Timothy Edwin Kelly | CFO & Treasurer | 1973 |
| 5. | Lauren Mastrocola | VP of Fin. & Principal Accounting Officer | NA |
| 6. | Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | NA |
| 7. | Alex Kane | VP of Investor Relations & Corp. Communications | NA |
| 8. | Mr. Alex Nemiroff J.D. | Gen. Counsel & Sec. | 1979 |
| 9. | Ms. Kelly McCue | Chief People Officer | NA |
| 10. | Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | 1975 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.040 0.054% | 75.01 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.314 0.430% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.505 0.334% | 450.78 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.130 3.270% | 498 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -214.029M | -167.061M | -61.828M | -35.596M | -26.402M |
| Minority Interest | - | - | - | - | - |
| Net Income | -213.072M | -166.879M | -61.82M | -35.512M | -26.535M |
| Selling General Administrative | 59.946M | 47.075M | 16.992M | 6.232M | 3.899M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.419M | 0.182M | 0.05M | 0.037M | 0.001M |
| Ebit | -215.405M | -167.514M | -62.018M | -35.789M | -26.275M |
| Ebitda | -214.986M | -167.332M | -61.968M | -35.559M | -26.274M |
| Depreciation And Amortization | 0.419M | 0.182M | 0.05M | 0.23M | 0.001M |
| Operating Income | -214.986M | -167.332M | -61.968M | -35.789M | -22.719M |
| Other Operating Expenses | 214.986M | 167.332M | 61.968M | 35.789M | 22.719M |
| Interest Expense | 0.419M | 0.182M | 0.19M | 0M | 0.127M |
| Tax Provision | 0M | 0M | -0.008M | -0.084M | 0.133M |
| Interest Income | - | - | 0.14M | 0.193M | 0.092M |
| Net Interest Income | - | - | 0.14M | 0.193M | -0.035M |
| Income Tax Expense | -0.957M | -0.182M | -0.008M | -0.084M | 0.133M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 214.986M | 167.332M | 61.968M | 35.789M | 22.719M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 0.957M | 0.271M | 0.14M | 0.193M | -3.648M |
| Net Income From Continuing Ops | -214.029M | -167.061M | -61.82M | -35.512M | -26.535M |
| Net Income Applicable To Common Shares | -214.029M | -167.061M | -70.323M | -40.682M | -29.223M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 87.948M | 115.128M | 292.747M | 303.177M | 47.694M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.58M | 10.351M | 11.498M | 5.718M | 0.681M |
| Total Liab | 18.279M | 39.022M | 41.935M | 15.72M | 7.581M |
| Total Stockholder Equity | 69.669M | 76.106M | 250.812M | 287.457M | 40.113M |
| Other Current Liab | 7.416M | 14.845M | 22.533M | 10.869M | 3.455M |
| Common Stock | 0.013M | 0.005M | 0.005M | 0.004M | 0.001M |
| Capital Stock | 0.013M | 0.005M | 0.005M | 0.004M | 0.001M |
| Retained Earnings | -653.921M | -530.644M | -316.615M | -149.554M | -81.009M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.416M | 0.472M | 0.769M | 0.62M |
| Cash | 81.3M | 61.615M | 138.704M | 296.608M | 44.815M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.749M | 35.522M | 37.624M | 15.72M | 6.818M |
| Current Deferred Revenue | 1.392M | 5M | - | - | - |
| Net Debt | -78.805M | -57.11M | -134.393M | -295.845M | -43.356M |
| Short Term Debt | 1.126M | 1.005M | 4.311M | 0.763M | 0.696M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.495M | 4.505M | 4.311M | 0.763M | 1.459M |
| Other Stockholder Equity | 723.577M | 606.918M | 567.598M | 437.007M | -121.083M |
| Property Plant Equipment | - | 0.971M | 4.866M | 0.836M | 1.578M |
| Total Current Assets | 84.88M | 110.84M | 287.409M | 302.326M | 45.496M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 38.874M | 137.207M | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 5.815M | 14.672M | 10.78M | 4.088M | 2.667M |
| Accumulated Other Comprehensive Income | - | -0.173M | -0.176M | -303.177M | -0.038M |
| Non Currrent Assets Other | 0.416M | 0.416M | 0.472M | 0.015M | 0.62M |
| Non Current Assets Total | 3.068M | 4.288M | 5.338M | 0.851M | 2.198M |
| Capital Lease Obligations | 2.495M | 3.5M | 4.311M | 0.763M | 1.459M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 97.333M | -139.47M | -139.47M | -0.103M | -0.063M |
| Total Cashflows From Investing Activities | 96.889M | -140.52M | 0.004M | -0.103M | -0.063M |
| Total Cash From Financing Activities | 10.465M | 107.586M | 304.416M | 60.388M | 37.804M |
| Net Income | -214.029M | -167.061M | -61.82M | -35.512M | -26.535M |
| Change In Cash | -77.689M | -157.488M | 251.793M | 26.865M | 17.02M |
| Begin Period Cash Flow | 139.72M | 297.208M | 45.415M | 18.55M | 1.53M |
| End Period Cash Flow | 62.031M | 139.72M | 297.208M | 45.415M | 18.55M |
| Total Cash From Operating Activities | -185.043M | -124.554M | -52.623M | -33.42M | -20.721M |
| Depreciation | 0.419M | 0.182M | 0.05M | 0.037M | 0.001M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 1.164M | 100.86M | -30M | - | - |
| Other Cashflows From Financing Activities | 0.904M | 1.872M | 133.53M | -0.103M | 37.804M |
| Capital Expenditures | 0.444M | 1.05M | 0.004M | 0.103M | 0.063M |
| Change In Working Capital | -1.781M | 16.133M | 3.24M | 0.745M | 1.459M |
| Other Non Cash Items | 1.755M | 1.412M | 0.696M | 0.642M | 0.127M |
| Free Cash Flow | -185.487M | -125.604M | -52.619M | -33.523M | -20.784M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 520522 |
| 2. | BlackRock Extended Mkt Composite | 1 year ago | 303703 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 237861 |
| 4. | Biotech Growth Ord | 1 year ago | 190100 |
| 5. | Renaissance Global Health Care | 1 year ago | 173868 |
| 6. | T. Rowe Price New Horizons | 1 year ago | 133805 |
| 7. | US Small-Cap Growth II Equity Comp | 1 year ago | 133805 |
| 8. | Franklin Biotechnology Discv A(acc)USD | 1 year ago | 94885 |
| 9. | Fidelity Extended Market Index | 1 year ago | 72297 |
| 10. | Invesco Dorsey Wright SmallCap Momt ETF | 1 year ago | 71412 |
| 11. | Franklin Biotechnology Discovery A | 1 year ago | 50404 |
| 12. | Heptagon Driehaus US Micro Cap Eq C$ Acc | 1 year ago | 47293 |
| 13. | BlackRock Extended Equity Market K | 1 year ago | 27220 |
| 14. | iShares Micro-Cap ETF | 1 year ago | 27070 |
| 15. | T. Rowe Price New Horizons Tr-Z | 1 year ago | 25683 |
| 16. | Invesco Dorsey Wright Healthcare MomtETF | 1 year ago | 25144 |
| 17. | Fidelity Total Market Index | 1 year ago | 23497 |
| 18. | Driehaus Micro Cap Growth USD | 1 year ago | 21639 |
| 19. | Bridgeway Ultra-Small Company Market | 1 year ago | 20373 |
| 20. | Fidelity Series Total Market Index | 1 year ago | 17949 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Adage Capital Partners Gp LLC | 1 year ago | 1393028 |
| 2. | Cormorant Asset Management, LLC | 1 year ago | 1310000 |
| 3. | Perceptive Advisors LLC | 1 year ago | 821589 |
| 4. | Vanguard Group Inc | 1 year ago | 744069 |
| 5. | Verition Fund Managegment, LLC | 1 year ago | 545408 |
| 6. | T. Rowe Price Associates, Inc. | 1 year ago | 535999 |
| 7. | Partner Fund Management LP | 1 year ago | 477605 |
| 8. | Orbimed Advisors, LLC | 1 year ago | 460512 |
| 9. | Velan Capital Investment Management LP | 1 year ago | 350666 |
| 10. | Kingdon Capital Management LLC | 1 year ago | 350000 |
| 11. | 5AM Venture Management, LLC | 1 year ago | 340000 |
| 12. | HHG PLC | 1 year ago | 310059 |
| 13. | Bank of America Corp | 1 year ago | 278862 |
| 14. | Driehaus Capital Management LLC | 1 year ago | 266496 |
| 15. | Octagon Capital Advisors LP | 1 year ago | 260000 |
| 16. | Tri Locum Partners LP | 1 year ago | 248761 |
| 17. | LAURION CAPITAL MANAGEMENT LP | 1 year ago | 225000 |
| 18. | Vestal Point Capital LP | 1 year ago | 210000 |
| 19. | CIBC Global Asset Management Inc | 1 year ago | 192304 |
| 20. | SILVERARC CAPITAL MANAGEMENT, LLC | 1 year ago | 190556 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...